| pubmed-article:20822376 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20822376 | lifeskim:mentions | umls-concept:C0019196 | lld:lifeskim |
| pubmed-article:20822376 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20822376 | lifeskim:mentions | umls-concept:C0017431 | lld:lifeskim |
| pubmed-article:20822376 | lifeskim:mentions | umls-concept:C0010181 | lld:lifeskim |
| pubmed-article:20822376 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:20822376 | lifeskim:mentions | umls-concept:C2004202 | lld:lifeskim |
| pubmed-article:20822376 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20822376 | pubmed:dateCreated | 2011-1-12 | lld:pubmed |
| pubmed-article:20822376 | pubmed:abstractText | Several treatment strategies for patients with chronic hepatitis C have been compared mainly in terms of their efficacy, and it has been found that pegylated interferon (IFN) plus ribavirin has become the standard therapy, but aged patients may not tolerate ribavirin and the cost-effectiveness of treatment should also be further considered. We conducted a study to evaluate the efficacy, safety, and cost-effectiveness of consensus IFN monotherapy with high-dose induction for patients with chronic hepatitis C in clinical practice. | lld:pubmed |
| pubmed-article:20822376 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20822376 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20822376 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20822376 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20822376 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20822376 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:20822376 | pubmed:issn | 1502-7708 | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:ShiratoriYasu... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:TakaguchiKoui... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:AokiNoriakiN | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:YabushitaKazu... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:SakaguchiKohs... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:ArakiYasuyuki... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:IwasakiYoshia... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:TanakaHironor... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:KawaguchiMits... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:KariyamaKazuy... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:AndoMasaharuM | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:KobashiHaruhi... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:IkeadaHiroshi... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:OkamotoRyo-Ic... | lld:pubmed |
| pubmed-article:20822376 | pubmed:author | pubmed-author:SakataTatsuro... | lld:pubmed |
| pubmed-article:20822376 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20822376 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:20822376 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20822376 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20822376 | pubmed:pagination | 79-90 | lld:pubmed |
| pubmed-article:20822376 | pubmed:meshHeading | pubmed-meshheading:20822376... | lld:pubmed |
| pubmed-article:20822376 | pubmed:meshHeading | pubmed-meshheading:20822376... | lld:pubmed |
| pubmed-article:20822376 | pubmed:meshHeading | pubmed-meshheading:20822376... | lld:pubmed |
| pubmed-article:20822376 | pubmed:meshHeading | pubmed-meshheading:20822376... | lld:pubmed |
| pubmed-article:20822376 | pubmed:meshHeading | pubmed-meshheading:20822376... | lld:pubmed |
| pubmed-article:20822376 | pubmed:meshHeading | pubmed-meshheading:20822376... | lld:pubmed |
| pubmed-article:20822376 | pubmed:meshHeading | pubmed-meshheading:20822376... | lld:pubmed |
| pubmed-article:20822376 | pubmed:meshHeading | pubmed-meshheading:20822376... | lld:pubmed |
| pubmed-article:20822376 | pubmed:meshHeading | pubmed-meshheading:20822376... | lld:pubmed |
| pubmed-article:20822376 | pubmed:meshHeading | pubmed-meshheading:20822376... | lld:pubmed |
| pubmed-article:20822376 | pubmed:meshHeading | pubmed-meshheading:20822376... | lld:pubmed |
| pubmed-article:20822376 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20822376 | pubmed:articleTitle | Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2. | lld:pubmed |
| pubmed-article:20822376 | pubmed:affiliation | Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. yiwasaki@cc.okayama-u.ac.jp | lld:pubmed |
| pubmed-article:20822376 | pubmed:publicationType | Journal Article | lld:pubmed |
